Reckitt Benckiser beats earnings forecasts

LONDON Wed Feb 13, 2013 2:12am EST

LONDON Feb 13 (Reuters) - Britain's Reckitt Benckiser beat full-year earning expectations as the maker of Strepsils and Mucinex benefited from an unusually heavy U.S. cold and flu season in the final quarter.

Full-year adjusted earnings per share was 264.4 pence, compared to Thomson Reuters I/B/E/S estimates of 246.8 pence and a company-supplied forecast of 249 pence.

An early and unusually intense flu season in North America has pushed up business for hospitals, pharmacies and the makers of tissues and cold remedies.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.